Yahoo
NYSE - Delayed Quote USD

Becton, Dickinson and Company (BDX)

184.74 -2.88 (-1.54%)
At close: September 4 at 4:00:03 PM EDT
187.06 +2.32 (+1.26%)
After hours: September 4 at 7:59:46 PM EDT
Trade BDX on Coinbase
Dividend
BDX announced a cash dividend of $1.05 with an ex-date of Sep. 9, 2026
Chart Range Bar
Loading chart for BDX

What's happening with BDX?

28m ago
Powered by Yahoo Scout

Becton, Dickinson and Company (BDX) has shown strong performance with a 28.9% increaseover the last three months, bolstered by solid Q3 earnings. The company is also taking proactive steps in healthcare safety through its founding role in the Medicinal Hazard Data Standardization Consortium.

Powered by Yahoo Scout
  • Previous Close 187.62
  • Open 185.42
  • Bid 184.12 x 20000
  • Ask 184.89 x 10000
  • Day's Range 184.05 - 187.13
  • 52 Week Range 127.59 - 193.07
  • Volume 1,439,059
  • Avg. Volume 2,120,672
  • Market Cap (intraday) 50.321B
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) 31.96
  • EPS (TTM) 5.78
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield 4.20 (2.24%)
  • Ex-Dividend Date Sep 9, 2026
  • 1y Target Est 195.67

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

www.bd.com

72,000

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BDX
22.72%
S&P 500 (^GSPC)
12.75%

1-Year Return

BDX
25.88%
S&P 500 (^GSPC)
18.71%

3-Year Return

BDX
10.47%
S&P 500 (^GSPC)
70.93%

5-Year Return

BDX
1.92%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 4.98B
Earnings 377M
Profit Margin 7.57%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
-5.0%
0.0%
5.0%

Analyst Insights

View More

Top Analyst

Evercore ISI Group
49/100
Latest Rating
Outperform

Analyst Price Targets

170.00 Low
195.67 Average
184.74 Current
225.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/31/2026
Analyst B of A Securities
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 185 -> 200

Statistics

View More

Valuation Measures

Annual
As of 5/11/2026
  • Market Cap

    51.08B

  • Enterprise Value

    67.18B

  • Trailing P/E

    32.44

  • Forward P/E

    14.10

  • PEG Ratio (5yr expected)

    1.11

  • Price/Sales (ttm)

    2.36

  • Price/Book (mrq)

    2.09

  • Enterprise Value/Revenue

    2.99

  • Enterprise Value/EBITDA

    13.65

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.19%

  • Return on Assets (ttm)

    4.34%

  • Return on Equity (ttm)

    6.61%

  • Revenue (ttm)

    22.48B

  • Net Income Avi to Common (ttm)

    1.65B

  • Diluted EPS (ttm)

    5.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    709M

  • Total Debt/Equity (mrq)

    68.84%

  • Levered Free Cash Flow (ttm)

    4.48B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

184.74 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Becton Dickinson Earnings: Course Correction On Track; Guidance Upgrade; Shares Cheap

    Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

    Rating
    Price Target
  • BD Begins Its Post-Life Sciences Era

    Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

    Rating
    Price Target
  • Raising EPS estimates

    Headquartered in Franklin Lakes, NJ, BD manufacturers and sells a broad range of medical equipment and supplies. It operates through four business segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional.

    Rating
    Price Target
  • Major stock indices have been dancing around a flat line Friday morning,

    Major stock indices have been dancing around a flat line Friday morning, although as noon approaches there appears to be a bit of move higher underway. Still, a quiet session may not be the worst thing to end a week that has had a downward bias. Week to date, the S&P 500 is off almost 2%, the Nasdaq is off almost 5%, the Dow Jones Industrial Average is essentially flat. Factors in play for investors include the ongoing struggle to decide how to next play the technology/AI trade for stocks like Micron (up 306% year to date) and Nvidia (up a mere 3%). And then there is the issue of interest rates, as January assumptions that one or two rate cuts were likely in 2026 have turned to a belief that no rate cuts are likely and, indeed, a rate hike may be in order. Next up is the war in Iran. Will it ever really 'end,' or will it have a tail that wags forever in the form of a volatile and unpredictable Strait of Hormuz? Those are all tough issues to ponder - and, before you know it, second-quarter earnings reports will be added to the daily newsflow. Here we are argue any even reasonably positive distraction from the above events would likely be good. In other areas of interest, Bitcoin is currently around $60,000 (down 31% YTD), crude oil is at $69 a barrel (up 19% YTD), the 10-year Treasury yield is at 4.37%, and the VIX Volatility Index is t a relatively calm 19.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: